Oltipraz - PharmaKing

Drug Profile

Oltipraz - PharmaKing

Alternative Names: PMK-N01GI1

Latest Information Update: 22 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmaKing
  • Class Chemoprotectants; Organic sulfur compounds; Pyrazines; Small molecules
  • Mechanism of Action Fatty acid inhibitors; Gene expression inhibitors; Glutathione transferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-alcoholic fatty liver disease

Most Recent Events

  • 22 Mar 2017 Phase-III development for Non-alcoholic fatty liver disease is ongoing in South Korea (PO)
  • 28 Feb 2014 Phase-III clinical trials in Non-alcoholic fatty liver disease in South Korea (PO)
  • 19 Feb 2014 PharmaKing plans a phase III trial for Non-alcoholic fatty liver disease in South Korea (NCT02068339)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top